Orphazyme A/S (ORPHY) Stock Analysis
DELISTED
What happened to Orphazyme A/S (ORPHY) stock?
Orphazyme A/S (ORPHY) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
P/E 21.68 means the share price is 21.68 times one year of earnings per share.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Orphazyme A/S (ORPHY). Orphazyme A/S is a Danish biopharmaceutical company focused on developing therapies for neurodegenerative rare diseases. Their lead candidate, Arimoclomol, targets diseases like Niemann-Pick disease type C and Amyotrophic Lateral Sclerosis.
Last analyzed: Mar 18, 2026Orphazyme A/S (ORPHY) Healthcare & Pipeline Overview
Orphazyme A/S ADR Information Unsponsored
Orphazyme A/S (ORPHY) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ORPH
ORPHY OTC Market Information
ORPHY trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy ORPHY shares?
No. ORPHY stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for ORPHY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ORPHY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Orphazyme A/S. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.